Clinical trial Recruiting at 2 sites Observational Ages 6 and up

Using patient-derived stem cells to grow optic vesicle organoids that model congenital eye malformations

Official title: Modeling Ocular Developmental Diseases From 3D Cultures of Optic Vesicle Organoids Derived From hiPSCs of Patients With Ocular Malformations

Run by University Hospital, Toulouse · NCT06408701 · Data updated 2026-11-12

This project uses a blood sample from people with congenital eye malformations to make stem cells and grow optic vesicle organoids to see if they reproduce the patients' developmental abnormalities.

Quick facts

Study typeObservational
Ages6 Years and up
SexAll
Enrollment20 (estimated)
SponsorUniversity Hospital, Toulouse
Academic / other
Locations2 sites (Clermont-Ferrand and 1 other locations)
StatusRecruiting
StartedNovember 5, 2024
Main results expectedMay 2, 2034
Study endsMay 2, 2034
Registry record updatedMarch 18, 2026
Trial IDNCT06408701 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Patients with ocular malformations who can provide informed consent (or have a legal representative provide consent) and are affiliated with a social security scheme are eligible.

Probably not a fit

Because the study collects samples for laboratory modeling, most participants should not expect direct clinical benefit from taking part.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will collect a blood sample from consenting patients with ocular malformations, reprogram blood cells into human induced pluripotent stem cells (hiPSCs), and grow three-dimensional optic vesicle–containing organoids. These patient-derived organoids will be analyzed for structural and molecular features that reflect the individual's developmental eye defect. The approach aims to overcome limits of animal models by providing a human tissue model to study disease mechanisms and test potential therapeutic interventions in the lab. The study is observational and focused on laboratory modeling rather than providing experimental treatments to participants.

Why it matters

Potential benefit: If successful, this method could reveal disease mechanisms and point to new therapeutic targets or personalized treatment strategies for people with congenital eye malformations.

How similar studies have gone: hiPSC-derived organoid approaches have shown promising results for modeling retinal and developmental disorders, but patient-derived optic vesicle organoids for congenital malformations are a relatively new and still-developing method.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Affiliated with a social security scheme.
* Patients with ocular malformations.
* Signed informed consent obtained from the patient and/or their legal representatives.

Exclusion Criteria:

* Inability to understand the nature and objectives of the study and/or difficulties in communicating with the investigator.
* Deprivation of liberty by judicial or administrative decision.
* Any other pathological or psychological condition deemed incompatible by the investigator for the proper conduct of the study.

Where it's running

  • CHU de Clermont-Ferrand - Hôpital d'Estaing
    Clermont-Ferrand, France
    Recruiting
  • Purpan University Hospital
    Toulouse, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.